Elizabeth Gattman, NP
Primary Care · Jamestown, NYNPI 1831620152
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 68.3% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $5,857, more than ten times the $435 reported in 2021. Among primary care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $39.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$7K
- Viiv Healthcare Company$2K
- AbbVie$363
- Merck$254
- AstraZeneca$160
- GSK$116
- plus $507 from 9 others
What the payments were for
- Consulting fees$3,45035%
- Travel & lodging$9179%
- Food & beverage$5,52356%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 102 | $6,756 |
| Viiv Healthcare Company | 83 | $1,735 |
| AbbVie | 17 | $363 |
| Merck | 16 | $254 |
| AstraZeneca | 5 | $160 |
| GSK | 1 | $116 |
| Lilly USA, LLC | 6 | $104 |
| Novo Nordisk | 4 | $81 |
| Pfizer | 4 | $75 |
| Hologic Sales And Service, LLC | 3 | $70 |
| EMD Serono, Inc. | 4 | $63 |
| Alkermes, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Johnson & Johnson | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yeztugo$4,400
- DOVATO$250
- TRELEGY ELLIPTA$116
How this compares
$9,890 in reported general payments places this provider in the 95th percentile of 239 primary care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 199 | $584,952 |
| DescovyEmtricitabine/Tenofov Alafenam | 195 | $435,668 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 101 | $398,957 |
| TivicayDolutegravir Sodium | 123 | $278,125 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 63 | $225,338 |
| CabenuvaCabotegravir/Rilpivirine | 32 | $196,038 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 47 | $172,306 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 41 | $164,276 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $62,108 |
| EliquisApixaban | 42 | $25,700 |
| IsentressRaltegravir Potassium | 13 | $24,638 |
| OzempicSemaglutide | 19 | $18,295 |
| RybelsusSemaglutide | 18 | $17,329 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $16,427 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $16,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Tivicay, Cabenuva, Triumeq | $1,735 | $1,231,421401 claims |
| GileadDescovy, Biktarvy, Genvoya | $6,756 | $998,901337 claims |
| Novo NordiskOzempic, Rybelsus | $81 | $35,62537 claims |
| MerckIsentress, Januvia | $254 | $34,59026 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $116 | $32,78262 claims |
| PfizerEliquis | $75 | $25,70042 claims |
| AstraZenecaFarxiga, Symbicort | $160 | $14,40237 claims |
| AbbVieCreon | $363 | $7,53011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 primary care providers in New York.
Other primary care in Jamestown
- Dorothy KleinertNew York$27K
- Stephanie KhanForest Hills$16K
- Albert MarcanoJackson Heights$15K
- Vanessa WangFlushing$10K
- Elizabeth SmithWaterloo$9K
- Eric RodriguezSyracuse$7K
- Natalie Sommerville-BrooksBrooklyn$6K
- Lisa PlanetaNew York$6K
- Pao-Ju TsengFlushing$6K
- Eliezer HernandezAlbany$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.